Spirapril

Spirapril

Systematic (IUPAC) name
(8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
Clinical data
Trade names	Renormax
AHFS/Drugs.com	International Drug Names
Pregnancy category	D
Legal status	℞ (Prescription only)
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	50%
Metabolism	converted to spiraprilat
Biological half-life	30 to 35 hours
Excretion	Hepatic and renal
Identifiers
CAS Number	83647-97-6 Y
ATC code	C09AA11 (WHO)
PubChem	CID: 5311447
IUPHAR/BPS	6575
DrugBank	DB01348 N
ChemSpider	4470933 Y
UNII	96U2K78I3V Y
KEGG	D08529 Y
ChEMBL	CHEMBL431 Y
Chemical data
Formula	C22H30N2O5S2
Molecular mass	466.616 g/mol
SMILES O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc3
InChI InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1 Y Key:HRWCVUIFMSZDJS-SZMVWBNQSA-N Y
NY (what is this?)  (verify)

Spirapril hydrochloride (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.

Spiraprilat — the active metabolite

Like many ACE inhibitors, this prodrug is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment. However, data on its effect upon the renal function are conflicting.